Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
MIRM Stock Chart & Stats
$99.27
-$0.27(-0.64%)
At close: 4:00 PM EST
$99.27
-$0.27(-0.64%)
Day’s Range― - ―
52-Week Range$36.88 - $99.44
Previous CloseN/A
Volume92.82K
Average Volume (3M)815.76K
Market Cap
$5.01B
Enterprise Value$5.25B
Total Cash (Recent Filing)$375.55M
Total Debt (Recent Filing)$318.76M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Mar 11, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding51,683,838
10 Day Avg. Volume712,316
30 Day Avg. Volume815,761
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)8.71
Price to Sales (P/S)5.83
P/FCF Ratio210.57
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue11.13
Enterprise Value/Gross Profit13.92
Enterprise Value/Ebitda-956.98
Forecast
1Y Price Target
$106.50Price Target Upside7.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentSuccessful mid-stage interim analyses and an independent committee's recommendation to expand volixibat reduce development risk and increase the chance that a confirmatory program could support a regulatory filing for primary sclerosing cholangitis.
Commercial OpportunityAbsence of any approved therapy for primary sclerosing cholangitis, together with established commercial infrastructure and strong hepatology key opinion leader relationships, positions the company to capture significant market share if volixibat is approved.
Pipeline And Acquisition SynergyAcquisition of Bluejay adds brelovitug with robust Phase 2 efficacy and regulatory breakthrough designations, strengthening the rare liver disease portfolio and providing multiple potential clinical readouts to drive value.
Bears Say
Commercial And Financial PressurePotential generic competition and ensuing legal disputes could pressure pricing, limit future revenue from the marketed product, and increase litigation costs.
Patent Invalidation ThreatA generic filing seeking to invalidate several method of treatment patents, including patents expiring in 2031, raises the prospect of accelerated generic entry and reduced exclusivity.
Patent Litigation RiskA Paragraph IV ANDA filing by a generic challenger introduces patent litigation risk that could threaten market exclusivity for the marketed liver therapy.
Mirum Pharmaceuticals News
MIRM FAQ
What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Mirum Pharmaceuticals Inc lowest stock price was $36.88 and its highest was $99.44 in the past 12 months.
What is Mirum Pharmaceuticals Inc’s market cap?
Mirum Pharmaceuticals Inc’s market cap is $5.01B.
When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
Mirum Pharmaceuticals Inc’s upcoming earnings report date is Mar 11, 2026 which is in 41 days.
How were Mirum Pharmaceuticals Inc’s earnings last quarter?
Mirum Pharmaceuticals Inc released its earnings results on Nov 04, 2025. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.19.
Is Mirum Pharmaceuticals Inc overvalued?
According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued.
Does Mirum Pharmaceuticals Inc pay dividends?
Mirum Pharmaceuticals Inc does not currently pay dividends.
What is Mirum Pharmaceuticals Inc’s EPS estimate?
Mirum Pharmaceuticals Inc’s EPS estimate is >-0.01.
How many shares outstanding does Mirum Pharmaceuticals Inc have?
Mirum Pharmaceuticals Inc has 51,683,838 shares outstanding.
What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
Mirum Pharmaceuticals Inc reported an EPS of $0.05 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went down -1.24%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MIRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mirum Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$106.50 (7.28% Upside)
$106.50 (7.28% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $9.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 29.7%
Last 30 Days ▲ 29.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
104.76%
12-Months-Change
Fundamentals
Return on Equity
-15.81%
Trailing 12-Months
Asset Growth
17.55%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
MIRM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Mirum Pharmaceuticals had a strong third quarter with significant revenue growth and positive net income for the first time. The company continues to advance its clinical pipeline and expand internationally. However, there are some challenges in revenue consistency and the adoption of genetic testing in certain segments.View all MIRM earnings summariesMIRM Stock 12 Month Forecast
Average Price Target
$106.50
▲(7.28% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Catalyst Pharma
―
Ultragenyx Pharmaceutical
―
ImmunityBio
―
Apellis Pharmaceuticals
―
Ownership Overview
Currently, No data available
---